Issue of Equity

    RNS Number : 1209Y
  EiRx Therapeutics PLC
  02 July 2008
   


    EIRX THERAPEUTICS PLC
    ("EiRx" or "the Company")
    Admission of shares

    Application has been made for the admission of 1,577,333,333 EiRx ordinary shares of 0.001p with admission expected to take place on 4
July 2008.

    The shares have been issued in satisfaction of amounts owed to EiRx Pharma Limited, a shareholder in the Company, as announced on 23 May
2008

    Upon admission of the new shares, EiRx Pharma Ltd will hold 2,245,083,333 ordinary shares in the Company, representing 26.25% of the
8,553,076,093 ordinary shares in issue.



    For further information, please contact:

 EiRx Therapeutics plc                      [phone]
 Colin Telfer PhD, Chief Executive Officer
                                                               
 Grant Thornton Corporate Finance           [phone]
                                                               
 Philip Secrett / Colin Aaronson


    ENDS


    Notes for Editors


    About EiRx
    EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing cutting-edge targeted therapies for the treatment of
cancer. Headquartered in Cork, Ireland, the Company conducts drug discovery focused on tumours arising due to anomalies in apoptosis and
cellular growth regulatory pathways, with particular relation to breast and colorectal tumours, currently two of the four leading causes of
death from cancer world-wide.

    EiRx is built on leading scientific expertise in the areas of apoptosis biology, cancer pathway biology, biomarker technologies and the
metabolic basis of drug resistance in tumours. It has established technical capabilities in target identification, validation and cell-based
screening, and is combining unique resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional genomics platform and the
Engineered Pathway Dependence ("EnPADTM") isogenic cellular screening technology to create a product development engine specialising in
discovery and development of small-molecule targeted cancer therapies and the discovery and validation of cancer biomarkers.

    For further information please see our website at http://www.eirx.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
LISKLLBBVDBLBBV